Form 4: Amgen SVP & CCO Nancy Grygiel Reports Stock and Option Awards

Nancy Grygiel, SVP & CCO of Amgen, reports the acquisition of restricted stock units and non-qualified stock options.

Summary

• On May 7, 2024, Nancy A. Grygiel, SVP & CCO of Amgen Inc., reported transactions involving Amgen's common stock and derivative securities.
• Grygiel acquired 499 shares of common stock as Restricted Stock Units (RSUs) that vest in three annual installments starting May 7, 2026.
• She also acquired 3,244 non-qualified stock options (NQSOs) with an exercise price of $300.3, also vesting in three annual installments starting May 7, 2026.
• Following these transactions, Grygiel directly owns 10,300 shares of Amgen common stock and indirectly owns 99.9653 shares through the 401(k) plan.
• She also directly owns 3,244 NQSOs.
• The report also mentions existing RSUs that will vest on various dates in 2024, 2025, 2026 and 2027.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock and options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of RSUs and stock options by a high-ranking executive could be interpreted as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs and stock options extend to 2028, suggesting a long-term incentive structure for the executive.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders. The granting of RSUs and stock options is a common practice in the biotechnology industry to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in large biotech companies like Amgen, mirroring practices at companies such as Gilead Sciences, Biogen, and Regeneron.
• The vesting schedules (three annual installments) are also typical, aligning with industry norms for long-term incentive plans.
• The specific number of options and RSUs granted would need to be compared against peer companies to determine if it is above or below average.

Stakeholder Impact

• The granting of RSUs and stock options aligns the executive's interests with those of shareholders, incentivizing them to increase shareholder value.

Key Dates